昌吉妇科正规的医院是哪个(昌吉多长时间可以打胎多) (今日更新中)

SAN FRANCISCO, Nov. 1 (Xinhua) -- Apple announced on Tuesday that its latest iPhone 4S smartphone will be available in China's Hong Kong, South Korea and 13 additional countries next Friday.Customers will be able to pre-order iPhone 4S beginning this Friday, the Cupertino, California-based company said in a statement.The other 13 countries are Albania, Armenia, Bulgaria, El Salvador, Greece, Guatemala, Malta, Montenegro, New Zealand, Panama, Poland, Portugal and Romania.So far, some owners have been complaining about the shorter battery life on their new iPhone 4S handsets. Apple is reportedly investigating the issue and has not made official comments yet.The iPhone 4S looks the same as the previous iPhone 4 but has major hardware upgrade inside. Apple announced sales of more than four million units of iPhone 4S in the three days after its launch in the United States on Oct. 14.The iPhone 4S now is available in 29 countries and is expected to arrive in stores in more than 70 countries by the end of this year.

BEIJING, Jan. 19 (Xinhua) -- China's major textile companies are expected to witness an annual increase of 8 percent in their value-added output over the next four years, the Ministry of Industry and Information Technology said Thursday.The ministry published a plan regarding supporting the development of the textile industry during the country's 12th Five-Year Plan period (2011-2015), according to which the sector's exports will reach 300 billion U.S. dollars by 2015 with an annual growth of 7.5 percent.The industry is also expected to employ 20 million people by 2015 and its energy consumption per unit of value-added output will drop by 20 percent from 2010, the guideline said.The country will encourage the textile industry to enhance brand-building and aims to build 5-10 textile companies of global influence and 50 companies with an annual revenue of more than 10 billion yuan by 2015.The guideline warned of potential risks for the sector, including volatile changes in raw material prices, rising production costs and a complicated international trade environment.The guideline said the industry should develop new products and explore new markets to ensure a healthy development during the coming period.

SHIJIAZHUANG, Oct. 16 (Xinhua) -- Chinese archaeologists said Sunday that they have found evidence of the cultivation of glutinous millet in the northern province of Hebei that could date back to 10,000 years, the earliest evidence of people growing the crop in the world.Lab results showed that remains of glutinous millet found at archaeological sites in Cishan Village in the city of Wu'an were harvested during the Neolithic Era between 8,700 to 10,000 years ago, scientists with the Institute of Geology and Geophysics of China Academy of Sciences (IGGCAS) said at a cultural festival held in Wu'an on Sunday.This means Cishan was the birthplace of the crop, archaeologists said.They have also found remains of foxtail millet in the pits, which could date back to between 8,700 and 7,500 years. This would be the earliest evidence of the crop's cultivation, which means that Cishan was the birthplace of foxtail millet, too, said Lu Houyuan, an IGGCAS scientist.Cultivating small-seeded dry crops was more prevalent than cultivating rice in prehistoric times, especially in China's semi-arid northern regions, Lu said.A total of 50,000 kilograms of grains have been stored in 88 pits for thousands of years at the Cishan Site, a Neolithic site discovered in 1972.In addition to grain remnants, pottery, stone tools, animal bones and bone artifacts have also been excavated from the site, which archaeologists believe will help their research in the emergence of agriculture in China.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Erwinaze to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy to E. coli derived asparaginase and pegapargase chemotherapy drugs used to treat ALL.Acute lymphoblastic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes, a type of white blood cell. White blood cells help the body fight infection and are formed in the bone marrow.Erwinaze is injected directly into the muscle three times a week and works by breaking down one of the body's protein building blocks (the amino acid, asparagine) that is present in the blood, and is necessary for the growth of all cells. Leukemia cells cannot produce this protein building block. When a patient is treated with Erwinaze the leukemia cells die. Normal human cells are able to make enough asparagine for their own needs through biosynthesis and will not be affected by treatment with Erwinaze."The approval of Erwinaze underscores the FDA's commitment to the approval of drugs for conditions with limited patient populations with unmet medical needs using novel trial endpoints," said Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.Side effects associated with Erwinaze treatment include serious allergic reactions, inflammation of the pancreas, high blood levels of liver enzymes, blood clotting, bleeding, nausea, vomiting and high blood sugar.

来源：资阳报